07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

CJ-12420: Phase III started

CJ began a double-blind, Korean Phase III trial to compare 100 mg oral CJ-12420 once daily vs. 40 mg oral esomeprazole once daily for up to 8 weeks in about 280 patients. The trial start...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

RQ-00000004: Phase I started

RaQualia began a Japanese Phase I trial of RQ-00000004. The product is in Phase II testing for GERD in Korea. CJ Group’s CJ CheilJedang Co. affiliate has exclusive rights to develop and commercialize RQ-00000004 in...
00:38 , Jun 18, 2013 |  BC Extra  |  Financial News

RaQualia looks to raise at least $35 million

Gastrointestinal company RaQualia Pharma Inc. (JASDAQ:4579) said it hopes to raise at least Y3.3 billion ($34.7 million) through the exercise of 2,500 stock acquisition rights by Merrill Lynch Japan Securities. Each right entitles Merrill to...
07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

RQ-00000004: Phase II started

RaQualia said that CJ Group's CJ CheilJedang Co. affiliate began a Korean Phase II trial of RQ-00000004. The trial start triggered an undisclosed milestone payment to RaQualia under a 2010 deal granting CJ CheilJedang exclusive...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

RaQualia gastrointestinal news

CJ Group (Seoul, South Korea) has exclusive rights to RaQualia's RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia under a 2011 deal. In 2010, RaQualia granted CJ Group's CJ CheilJedang Co. affiliate exclusive rights...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

RaQualia infectious, neurology, gastrointestinal news

RaQualia said it will reduce headcount by about 12 (14%) to 70 in 2013 to focus on four compounds in early stage development for gastrointestinal diseases. The cuts include the elimination of nine R&D-related positions....
07:00 , Aug 1, 2011 |  BC Week In Review  |  Company News

CJ, RaQualia deal

RaQualia granted CJ Group exclusive rights to develop, manufacture and commercialize RaQualia's RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia. RaQualia will receive an upfront payment and is eligible for developmental milestones and royalties....
23:46 , Jul 29, 2011 |  BC Extra  |  Company News

RaQualia, CJ Group in gastrointestinal deal

RaQualia Pharma Inc. (JASDAQ:4579) granted CJ Group (Seoul, South Korea) exclusive rights to develop, manufacture and commercialize RaQualia's gastrointestinal candidate RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia. RaQualia will receive an upfront payment...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

RQ-00000004: Phase I data

A U.S. Phase I trial in healthy male volunteers showed that single ascending-doses of up to 300 mg oral RQ-00000004 were well tolerated. Additionally, single doses of >=30 mg RQ-00000004 increased gastric pH to >6...